Chronic lymphocytic leukemia with 17p deletion

Chronic lymphocytic leukemia with 17p deletion refers to a high-risk molecular subtype of chronic lymphocytic leukemia, an indolent hematologic malignancy of older adults characterized by the progressive accumulation of monoclonal, mature-appearing B lymphocytes in the blood, bone marrow, and secondary lymphoid tissues This subtype is defined by the cytogenetic loss of the short arm of chromosome 17 [del(17p)], a critical genomic locus containing the *TP53* tumor suppressor gene

Chronic lymphocytic leukemia with 17p deletion refers to a high-risk molecular subtype of chronic lymphocytic leukemia, an indolent hematologic malignancy of older adults characterized by the progressive accumulation of monoclonal, mature-appearing B lymphocytes in the blood, bone marrow, and secondary lymphoid tissues

This subtype is defined by the cytogenetic loss of the short arm of chromosome 17 [del(17p)], a critical genomic locus containing the *TP53* tumor suppressor gene Impairment of p53-dependent cell cycle arrest and apoptosis leads to marked genomic instability, aggressive disease biology, increased propensity for disease progression, and inherent resistance to standard chemoimmunotherapy regimens

Impairment of p53-dependent cell cycle arrest and apoptosis leads to marked genomic instability, aggressive disease biology, increased propensity for disease progression, and inherent resistance to standard chemoimmunotherapy regimens

Impairment of p53-dependent cell cycle arrest and apoptosis leads to marked genomic instability, aggressive disease biology, increased propensity for disease progression, and inherent resistance to standard chemoimmunotherapy regimens